All companies
Guardant Health logo🇺🇸

Guardant Health

Precision oncology company making blood tests for cancer screening, monitoring and treatment selection.

CorporateEstablished🇺🇸 Palo Alto, California
2012Founded
1,000+Team size
3Products & services

About

Guardant Health is a precision oncology company based in Palo Alto, California. It provides blood and tissue tests for cancer screening, for monitoring early-stage cancer and for guiding treatment in advanced cancer. The company was founded in 2012 and is listed on Nasdaq under the ticker GH. It has offices in the United States, Singapore, Japan, China, India and Israel.

Products

product

Shield

FDA-approved blood test for colorectal cancer screening.

+ What's included
For: People eligible for colorectal cancer screening
  • Blood-based screening test
  • Analyses cell-free DNA from a blood sample
product

Guardant360

Liquid biopsy and tissue tests that help inform treatment decisions in advanced cancer.

+ What's included
For: Patients with advanced solid tumors and their doctors
  • Guardant360 CDx is an FDA-approved liquid biopsy
  • Liquid results in less than 7 days
  • Guardant360 Tissue combines DNA, RNA and epigenomics
product

Guardant Reveal

Blood test that uses circulating tumor DNA to detect cancer at the molecular level.

+ What's included
For: Patients with early-stage or advanced cancer
  • Minimal residual disease detection
  • Recurrence monitoring in early-stage cancer
  • Therapy response monitoring in advanced cancer

Customers

Doctors order its tests for patients with early or advanced cancer and for people eligible for colorectal cancer screening.

Traction

Updated Oct 2026
1,000,000+blood tests performed
12,000doctors who have ordered its tests

Team1 on Openfor

DM
Daniel MaggsDirector, Biopharma Business Development

Open topick one to start a conversation

Hiring
The careers page lists open positions and a talent community.In the company's own words
Openfor.co network

Put your company on Openfor. Get found.

Show your products, customers and traction to founders, investors and partners across 30+ countries.